Koninklijke Philips N.v Stock Earnings Reports

Philips delivered a strong start to 2026 with order intake up 6% and comparable sales up 4% in Q1, driven by Personal Health, strong North American demand and momentum in Image Guided Therapy and Connected Care monitoring. Adjusted EBITDA margin expanded 40 bps to 9.0% (with segment margins up in Diagnosis & Treatment and Personal Health) despite tariff and input-cost headwinds. Innovation and regulatory progress accelerated (20 FDA 510(k)/PMAs in Q1), including helium-free MRI leadership (BlueSeal), spectral CT (Verida) introductions, and AI-enabled workflows (SmartHeart, DeviceGuide). Philips reiterated full-year guidance: comparable sales growth of 3.0–4.5%, adjusted EBITDA margin 12.5–13.0%, and free cash flow EUR 1.3–1.5bn, while noting ongoing risks from Middle East developments, China centralized procurement pressure (notably CT and ultrasound), tariffs, freight and components inflation. Productivity programs (EUR 126m delivered in Q1; on track for long-term savings) and selective pricing, supply-chain optimization and AI-enabled efficiencies are the key mitigation levers. Balance sheet highlights: cash EUR 2.6bn, net debt EUR 5.5bn, leverage ~1.8x. Management emphasizes disciplined, platform-focused strategy, continued customer partnerships, and execution to hit full-year targets despite macro uncertainty.